EpilepsyGTx

EpilepsyGTx is a pioneering biotechnology research company dedicated to transforming the management of focal refractory epilepsy (FRE). With a commitment to innovation, EpilepsyGTx is developing cutting-edge gene therapies designed to provide seizure-free outcomes for patients. Our mission is to make patients with focal refractory epilepsy seizure-free.

Located in Cambridge, EpilepsyGTx is strategically positioned within a hub of scientific and technological advancement. The primary address is Cambridge Research Park, Beach Drive, Building 1000, Cambridge, CB25 9PD, GB. EpilepsyGTx leverages its location to foster collaboration and drive breakthroughs in gene therapy research. The team is focused on advancing its late preclinical-stage programs towards clinical applications, ensuring that transformative treatments become a reality for those in need.

EpilepsyGTx is poised for significant growth and commercial development within the biotechnology sector. The company's dedication to innovation and patient outcomes positions EpilepsyGTx as a key player in the future of epilepsy management. We invite the management team at EpilepsyGTx to create a customized and exclusive company showcase and product listing on our platform, highlighting your groundbreaking work in biotechnology research.